Sarah Denman 1 , Tariq El-Shanaway 2 , Emily Carne 2 , Lisa Devlin 3 , Sinisa Savic 4 Show Affiliations »
Abstract
INTRODUCTION: Due to perceived risk of anaphylaxis, home treatment with omalizumab has been limited. Within the UK, most centres administer omalizumab in a hospital setting. However, the reported prevalence of anaphylaxis is low and in December 2018 home treatment became licensed. A home treatment pathway was previously reported by one UK centre, and this update describes three UK centres' experience of home omalizumab treatment. METHODS: The medical records of omalizumab patients were retrospectively reviewed. RESULTS: A total of 137 adult patients have received home omalizumab treatment; home treatment duration 0-44 months. There was no increase in adverse effects seen in patients treated at home. There were no reported adherence issues and no reduction in efficacy. Patients report they prefer home treatment due to increased flexibility and reduced impact on daily life/work. CONCLUSION: Home treatment with omalizumab is a safe and effective alternative to hospital administration. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.
INTRODUCTION: Due to perceived risk of anaphylaxis , home treatment with omalizumab has been limited. Within the UK, most centres administer omalizumab in a hospital setting. However, the reported prevalence of anaphylaxis is low and in December 2018 home treatment became licensed. A home treatment pathway was previously reported by one UK centre, and this update describes three UK centres' experience of home omalizumab treatment. METHODS: The medical records of omalizumab patients were retrospectively reviewed. RESULTS: A total of 137 adult patients have received home omalizumab treatment; home treatment duration 0-44 months. There was no increase in adverse effects seen in patients treated at home. There were no reported adherence issues and no reduction in efficacy. Patients report they prefer home treatment due to increased flexibility and reduced impact on daily life/work. CONCLUSION: Home treatment with omalizumab is a safe and effective alternative to hospital administration. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Entities: Disease
Species
Keywords:
anaphylaxis; chronic spontaneous urticaria; efficacy; home treatment; omalizumab
Year: 2019
PMID： 33097621 PMCID： PMC7856134 DOI： 10.1136/ejhpharm-2019-001914
Source DB: PubMed Journal: Eur J Hosp Pharm ISSN： 2047-9956